10/13/2010

Celgene filed a lawsuit against Natco Pharma after the latter sought FDA approval to market a generic version of Revlimid, the former's treatment for multiple myeloma. Celgene said Natco's copy would infringe on 10 patents that expire between 2016 and 2026.

Related Summaries